Seleaina Thomas
Family · Victorville, CANPI 1871790444
Payments from drug & device makers
Across 291 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$1K
- UCB, Inc.$727
- Mallinckrodt Hospital Products Inc.$686
- Bayer$632
- GSK$422
- plus $2K from 17 others
What the payments were for
- Consulting fees$1752%
- Travel & lodging$30%
- Food & beverage$7,04296%
- Education$921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 69 | $1,600 |
| AbbVie | 44 | $1,215 |
| UCB, Inc. | 23 | $727 |
| Mallinckrodt Hospital Products Inc. | 25 | $686 |
| Bayer | 30 | $632 |
| GSK | 21 | $422 |
| Lilly USA, LLC | 5 | $388 |
| Vision Quest Industries Inc. | 14 | $235 |
| ANI Pharmaceuticals, Inc. | 13 | $222 |
| Pfizer | 8 | $205 |
| Boehringer Ingelheim | 3 | $171 |
| Medtronic | 9 | $160 |
| Shield Therapeutics Inc | 4 | $151 |
| Novartis | 7 | $143 |
| Aurinia Pharma U.S., Inc. | 5 | $130 |
| Novo Nordisk | 3 | $59 |
| AstraZeneca | 2 | $38 |
| Abbott | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Mycovia Pharmaceuticals, Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Cranial Technologies, Inc | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,312 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 454 | $3,262,792 |
| ActharCorticotropin | 36 | $3,036,354 |
| Enbrel SureclickEtanercept | 173 | $1,311,907 |
| RinvoqUpadacitinib | 167 | $1,081,910 |
| Cosentyx Sensoready PenSecukinumab | 31 | $458,377 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $458,336 |
| BenlystaBelimumab | 78 | $382,056 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 128 | $316,876 |
| Orencia ClickjectAbatacept | 50 | $288,870 |
| Xeljanz XrTofacitinib Citrate | 29 | $173,174 |
| Taltz AutoinjectorIxekizumab | 21 | $146,173 |
| Cimzia (2 Pack)Certolizumab Pegol | 17 | $92,399 |
| Humira(Cf)Adalimumab | 14 | $91,931 |
| KerendiaFinerenone | 122 | $80,138 |
| NucalaMepolizumab | 15 | $78,899 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $686 | $3,036,35436 claims |
| AbbVieRinvoq, Humira(Cf), Restasis | $1,215 | $1,181,596193 claims |
| GSKBenlysta, Nucala, Trelegy Ellipta | $422 | $469,650106 claims |
| AmgenEvenity (2 Syringes), Prolia | $1,600 | $387,110167 claims |
| Lilly USA, LLCForteo, Mounjaro, Trulicity | $388 | $120,04162 claims |
| UCB, Inc.Cimzia (2 Pack) | $727 | $92,39917 claims |
| BayerKerendia | $632 | $80,138122 claims |
| Novo NordiskOzempic | $59 | $46,15744 claims |
| Boehringer IngelheimJardiance | $171 | $30,59046 claims |
| PfizerNurtec Odt | $205 | $19,95312 claims |
| NovartisEntresto | $143 | $9,87114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Victorville
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.